Company Beijing Sun-Novo Pharmaceutical Research Co., Ltd.

Equities

688621

CNE100005139

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Ratings for Beijing Sun-Novo Pharmaceutical Research Co., Ltd.

EPS Revisions

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research

BEIJING SUN-NOVO PHARMACEUTICAL RESEARCH CO., LTD.

End-of-day quote Shanghai S.E. Other stock markets 03:30:00 28/06/2024 am IST			5-day change	1st Jan Change
42.7 ^CNY	-1.29%		-8.96%	-38.78%

25/04	Beijing Sun-Novo Pharmaceutical Research Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
26/02	Beijing Sun-Novo Pharmaceutical Research Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Beijing Sun-Novo Pharmaceutical Research Co Ltd is a China-based company principally engaged in the provision of preclinical and integrated clinical research and development services for pharmaceuticals. The Company's main businesses cover comprehensive research and development services in innovative drug development, generic drug development and consistency assessment. The Companyâs services mainly comprise drug discovery, pharmacology and pharmacodynamics, pharmacy research, clinical research and bioanalysis. The Company provides services in pharmacological research, including raw drugs preparation process and structure confirmation, dosage selection, medical services, operational services, data management and statistical analysis services, risk management services and quality management. The Company mainly conducts its businesses in the domestic market.

Number of employees: 1,370

CNY in Million	2022	Weight	2023	Weight	Delta
Pharmaceutical Research Services 61.0 %	442	65.3 %	569	61.0 %	+28.67%
Clinical Trials and Bioanalytical Services 38.9 %	234	34.7 %	362	38.9 %	+54.54%
Other Business 0.1 %	0	0.0 %	1	0.1 %	+436.77%

CNY in Million	2022	Weight	2023	Weight	Delta
China 100.0 %	677	100.0 %	932	100.0 %	+37.76%

Managers	Title	Age	Since
Yu Jing Liu CEO	Chief Executive Officer	42	01/09/01
Ling Yang Zhao DFI	Director of Finance/CFO	36	21/20/21
Ming Juan Wang CTO	Chief Tech/Sci/R&D Officer	48	-
Guang Tao Hao PRN	Corporate Officer/Principal	44	21/20/21

Members of the board	Title	Age	Since
Qian Li CHM	Chairman	43	09/09/09
Qiao Chen BRD	Director/Board Member	44	21/20/21
Zhuang Kun He BRD	Director/Board Member	52	21/20/21
Wen Ran Li BRD	Director/Board Member	41	21/20/21
Ling Yang Zhao DFI	Director of Finance/CFO	36	21/20/21
Yu Jing Liu CEO	Chief Executive Officer	42	01/09/01
Ying Zhang BRD	Director/Board Member	38	21/20/21
Dan Dan Wang CHM	Chairman	42	01/10/01
Jin Feng Zhang BRD	Director/Board Member	40	01/17/01
Hui Ting Zhu BRD	Director/Board Member	41	09/22/09

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	112,000,000	60,981,241 ( 54.45 %)	0	54.45 %

Name	Equities	%	Valuation
Fullgoal Fund Management Co., Ltd. 13.30 %	10,783,184	13.30 %	74 M ¥
Yu Jing Liu 5.611 %	4,550,386	5.611 %	31 M ¥
Basic Pension Insurance Fund 16022 Portfolio 4.510 %	3,657,454	4.510 %	25 M ¥
Yan Shao 4.143 %	3,360,000	4.143 %	23 M ¥
Rongtong Fund Management Co., Ltd. 4.031 %	3,269,397	4.031 %	22 M ¥
Xin Quan Tuo 3.112 %	2,524,000	3.112 %	17 M ¥
Essence Fund Co., Ltd. 3.035 %	2,461,325	3.035 %	17 M ¥
GF Xinde Investment Management Co. Ltd. 2.775 %	2,250,896	2.775 %	15 M ¥
Wuhan State Owned Assets Sup. & Adm. Commssion 2.702 %	2,191,007	2.702 %	15 M ¥
Tianjin Hidea Venture Capital Investment Management Co. Ltd. 2.602 %	2,110,472	2.602 %	14 M ¥

Name	Equities	%	Valuation
Qian Li 100.00 %	30,897,300	100.00 %	211 M ¥

Beijing Sun-Novo Pharmaceutical Research Co., Ltd.

1st Floor, Building 7 79 Shuangying West Road

102200, Beijing

http://www.sun-novo.com

address Beijing Sun-Novo Pharmaceutical Research Co., Ltd.(688621)

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

42.7

Average target price

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
BEIJING SUN-NOVO PHARMACEUTICAL RESEARCH CO., LTD.	-38.78%	67Cr
LONZA GROUP AG	+38.65%	3.91TCr
IQVIA HOLDINGS INC.	-8.62%	3.88TCr
ALNYLAM PHARMACEUTICALS, INC.	+26.95%	3.12TCr
ICON PUBLIC LIMITED COMPANY	+10.74%	2.59TCr
CELLTRION, INC.	-13.50%	2.58TCr
UNITED THERAPEUTICS CORPORATION	+44.87%	1.41TCr
MEDPACE HOLDINGS, INC.	+34.36%	1.31TCr
BIO-TECHNE CORPORATION	-7.14%	1.13TCr
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-12.61%	1.07TCr

Other Biotechnology & Medical Research